Tianshu S. Liu

180 Fenglin Road
Zhongshan, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 39 publications

Association between cholesterol and liver injury risk in solid cancer patients treated with PD-1 inhibitors: evidence from two cohort studies.

Association between cholesterol and liver injury risk in solid cancer patients treated with PD-1 inhibitors: evidence from two cohort studies.

Journal: BMC cancer

Published: January 12, 2026

Targeting ATF3-mediated asparagine biosynthesis reverses acquired resistance to KRASG12C inhibitors.

Targeting ATF3-mediated asparagine biosynthesis reverses acquired resistance to KRASG12C inhibitors.

Journal: Oncogene

Published: December 28, 2025

Mechanistic insights into PD-1 inhibitor-associated immune thrombocytopenia: a case report integrating longitudinal transcriptomic profiling.

Mechanistic insights into PD-1 inhibitor-associated immune thrombocytopenia: a case report integrating longitudinal transcriptomic profiling.

Journal: Journal for immunotherapy of cancer

Published: December 09, 2025

Efficacy and safety of infigratinib in patients with refractory advanced gastric or gastroesophageal junction adenocarcinoma harboring FGFR2 gene amplification: a single-arm, multicenter phase 2 trial.

Efficacy and safety of infigratinib in patients with refractory advanced gastric or gastroesophageal junction adenocarcinoma harboring FGFR2 gene amplification: a single-arm, multicenter phase 2 trial.

Journal: British journal of cancer

Published: April 15, 2025

Phase-Change-Assisted Electrostatic Doping Enabling Nonvolatile Programmability of 2D Materials.

Phase-Change-Assisted Electrostatic Doping Enabling Nonvolatile Programmability of 2D Materials.

Journal: Small (Weinheim an der Bergstrasse, Germany)

Published: February 14, 2025

Perioperative nivolumab and chemotherapy in locally advanced squamous cell carcinoma of the oesophagus: a randomized multicentre phase 2 study with circulating tumor DNA dynamics monitoring.

Perioperative nivolumab and chemotherapy in locally advanced squamous cell carcinoma of the oesophagus: a randomized multicentre phase 2 study with circulating tumor DNA dynamics monitoring.

Journal: Molecular cancer

Published: February 07, 2025

Synergistic effects of PD-1 antibody and chemotherapy followed by surgery-centric local treatment in patients with limited-metastatic gastric or gastroesophageal adenocarcinoma (ROSETTE trial): an open-label, single-center, randomized phase 2 trial.

Synergistic effects of PD-1 antibody and chemotherapy followed by surgery-centric local treatment in patients with limited-metastatic gastric or gastroesophageal adenocarcinoma (ROSETTE trial): an open-label, single-center, randomized phase 2 trial.

Journal: BMC cancer

Published: November 05, 2024

Tofacitinib for the treatment of immune-related adverse events in cancer immunotherapy: a multi-center observational study.

Tofacitinib for the treatment of immune-related adverse events in cancer immunotherapy: a multi-center observational study.

Journal: Journal of translational medicine

Published: June 17, 2024

Pharmacokinetics of infigratinib and its active metabolites in Chinese patients with advanced gastric cancer harboring FGFR2 gene amplification.

Pharmacokinetics of infigratinib and its active metabolites in Chinese patients with advanced gastric cancer harboring FGFR2 gene amplification.

Journal: Clinical and translational science

Published: April 21, 2024

Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study.

Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study.

Journal: Nature communications

Published: March 09, 2024

Nivolumab plus anlotinib hydrochloride in advanced gastric adenocarcinoma and esophageal squamous cell carcinoma: the phase II OASIS trial.

Nivolumab plus anlotinib hydrochloride in advanced gastric adenocarcinoma and esophageal squamous cell carcinoma: the phase II OASIS trial.

Journal: Nature communications

Published: January 30, 2024

d-mannose targets PD-1 to lysosomal degradation and enhances T cell-mediated anti-tumor immunity.

d-mannose targets PD-1 to lysosomal degradation and enhances T cell-mediated anti-tumor immunity.

Journal: Cancer letters

Published: September 29, 2023

Showing 1-12 of 39

Last Updated: 09/26/2026